Michael Wacker

Dr. Michael Wacker is an experienced life science entrepreneur who joined Biomed in 2019. Michael successfully built up various start-up companies. In addition, he coaches start-ups in Switzerland for Innosuisse, the governmental commission of technology and innovation. Currently he is co-founder and member of the board of directors of Limmatech Biologics, Inura Medical and chairman of the board of Inositec.

Previously he was board member and chief business officer of Polyneuron Pharmaceuticals, a spin-off company of the university of Basel. Before joining Polyneuron, he was founder, board member and CSO of GlycoVaxyn, a vaccine development company that was acquired by GSK in 2015 and which valued the company at $212 million. Michael co-founded GlycoVaxyn in 2004 as a Spin-off company from the Swiss Federal Institute of Technology Zurich (ETHZ). Michael holds a M.Sc. in biochemistry and completed his Ph.D. and post-doctoral fellowship in microbiology at ETHZ. He is the author of several publications in international scientific journals, including Science and PNAS, as well as inventor of various patent applications.